PTCT— PTC THERAPEUTICS, INC.

MaterialsBiotechnology$6.2B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$1.73B+114.5%	$806.8M-14.0%	$937.8M+34.2%	$698.8M
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets	$47.0M-18.1%	$57.4M-12.4%	$65.5M	—
Amortization of acquired intangible assets	$24.7M-59.3%	$60.7M-72.7%	$222.6M+91.0%	$116.6M
Research and development	$455.2M-14.8%	$534.5M-19.8%	$666.6M+2.3%	$651.5M
Selling, general and administrative	$347.1M+15.4%	$300.9M-9.5%	$332.5M+2.0%	$326.0M
Change in the fair value of contingent consideration	-$800K+82.1%	-$4.5M+96.5%	-$127.7M-393.1%	-$25.9M
Intangible asset impairment	$159.5M-26.7%	$217.8M	—	$33.4M
Tangible asset impairment and (gains) losses on transactions, net	-$9.6M-1383.6%	$750K	—	—
Total operating expenses	$863.7M-22.1%	$1.11B-19.5%	$1.38B+20.2%	$1.15B
Income (loss) from operations	$866.9M+386.5%	-$302.6M+31.2%	-$439.5M+1.8%	-$447.4M
Interest expense, net	-$152.2M+8.8%	-$167.0M-29.3%	-$129.2M-42.2%	-$90.9M
Other (expense) income, net	-$18.1M-376.4%	$6.5M-35.4%	$10.1M+120.6%	-$49.2M
Gain on sale of priority review voucher	$99.9M	—	—	—
Loss on extinguishment of debt	-$137.6M	—	—	—
Income (loss) before income tax (expense) benefit	$696.6M+291.8%	-$363.1M+47.8%	-$696.1M-18.5%	-$587.5M
Income tax (expense) benefit	-$14.0M-7840.3%	-$176K-100.3%	$69.5M+144.1%	$28.5M
Net income (loss) attributable to common stockholders	$682.6M+287.9%	-$363.3M+42.0%	-$626.6M-12.1%	-$559.0M
Basic (in shares)	79.53B+3.5%	76.85B+2.7%	74.84B+104235.3%	71.7M
Diluted (in shares)	88.31B+14.9%	76.85B+2.7%	74.84B+104235.3%	71.7M
Net product revenue
Collaboration and license revenue
Royalty revenue
Translarna
Manufacturing revenue

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.